New Release: Stop splitting QC across spreadsheets and screens. Native QC Workspace is now live in TransLABtor. Learn how it holds upcoming patient results
Practical, study-style articles for laboratory supervisors, QA, and laboratory IT — what sits between analyzers and the LIS, how to specify uplinks, and how to run autoverification and QC gating you can defend. Written for clinical labs worldwide.
Customer notice, 26 October 2026. TransLABtor does not use PHP. Sites run Node.js 26, and the Node.js Brotli memory-leak issue does not apply to the way TransLABtor uses that runtime.
For lab techs, supervisors, and QA: native Westgard multirules, multi-level Levey–Jennings, CAPA review, and optional holds on upcoming patient results — inside middleware, not a spreadsheet.
Decision criteria for pausing AV by assay, instrument, or globally: QC failure, rule escapes, firmware change, hypercare — plus resume evidence and SOP language.
Translate an analyzer Host Interface Manual into a one-page IT brief: ports, session roles, protocols, identifiers, and mapping risks — before connect.
After connectivity works, encode QC gating and a narrow AV v1 with lab ownership, versioning, and explicit non-goals — before expanding rules.
How labs build defensible evidence around middleware: rule versions, QC gates, validation records, and release trails — without binder chaos.
A phased approach for lab supervisors and IT: pilot analyzer, parallel path, cutover slices, rollback criteria — without a big-bang weekend.
Lab IT patterns for protecting PHI on the analyzer LAN: segmentation, middleware host hardening, LIS allow-lists, identity, logs, and vendor remote — worldwide, on-premise first.
What lab supervisors and lab IT should require in a LIS uplink: message types, ACKs, code ownership, corrections, downtime behaviour, and golden-message evidence.
Middleware projects spiral when scope and testing come late. A five-phase path from instrument inventory to go-live for lab middleware — for lab supervisors and IT worldwide.
Why laboratory QC belongs on the result-release path: Westgard-style evaluation, failed/overdue gating of autoverification, and evidence supervisors can defend.
Interface debt between analyzers and the LIS quietly kills order-to-reportable turnaround: why point-to-point breaks, and how laboratory middleware pays the debt down.
How clinical labs design autoverification: rule families, QC gating, validation, and exception queues — so automatic release stays defensible for supervisors and QA.
Laboratory middleware sits between analyzers and the LIS: interfaces, autoverification, and QC in the release path. What it does, what it doesn't, and how supervisors and lab IT should evaluate it.
Talk with the engineering team about connectivity, uplink specs, and release controls — without replacing your LIS.
